Drug Profile
Fanotaprim - Vyera Pharmaceuticals
Alternative Names: TRC-2533; TRC-2533-NX; TUR-006; VYR-006Latest Information Update: 04 Jan 2023
Price :
$50
*
At a glance
- Originator Vyera Pharmaceuticals
- Class Antiparasitics; Diamines; Ethers; Piperazines; Pyrimidines; Small molecules
- Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Toxoplasmosis
Most Recent Events
- 04 Jan 2023 Fanotaprim is still in phase I trials for Toxoplasmosis in Canada (Vyera pharmaceuticals pipeline, January 2023)
- 04 Jan 2023 Vyera pharmaceuticals completes a phase I trial in Toxoplasmosis in Canada, before January 2023 (Vyera pharmaceuticals pipeline, January 2023)
- 11 Feb 2022 Chemical structure information added